# BRAF V600E and Redifferentiation Therapy in Radioiodine-refractory Papillary Thyroid Cancer

> **NCT03363347** · — · COMPLETED · sponsor: **Heidelberg University** · enrollment: 25 (actual)

## Conditions studied

- Thyroid Cancer

## Interventions

- **DRUG:** Redifferentiation with retinoid acid

## Key facts

- **NCT ID:** NCT03363347
- **Lead sponsor:** Heidelberg University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01-01
- **Primary completion:** 2014-12-31
- **Final completion:** 2014-12-31
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2017-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03363347

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03363347, "BRAF V600E and Redifferentiation Therapy in Radioiodine-refractory Papillary Thyroid Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03363347. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*